Furthermore, SpiD3 attenuated NFκB activation independent of TME support and displayed antitumor properties in ibrutinib-resistant cells, underlining its activity against proliferative and/or drug-resistant CLL cells. This evidence concerns the gene NFKB1 and B-cell chronic lymphocytic leukemia.